GlassScriptPhysician profile
Minsung Jeong
NPI 1902636194
$1,954.81
in general payments reported to CMS, 2019-2025
28 companies · $1,955 in 2025
The $1,955 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,657 · Education: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,656.82 |
| Education | $297.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $209.07 | 2025 | Enhertu, Datroway |
| Janssen Biotech, INC. | $207.98 | 2025 | Erleada, Darzalex, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $194.61 | 2025 | Imfinzi, Enhertu, Tagrisso |
| Jazz Pharmaceuticals INC. | $134.46 | 2025 | |
| Astellas Pharma US INC | $126.65 | 2025 | Vyloy |
| Novartis Pharmaceuticals Corporation | $120.65 | 2025 | |
| Merck Sharp & Dohme LLC | $111.13 | 2025 | Keytruda, Lynparza |
| Seagen INC. | $99.00 | 2025 | |
| Eisai INC. | $95.22 | 2025 | |
| Stemline Therapeutics INC. | $74.72 | 2025 | Orserdu, Elzonris |
| Taiho Oncology, INC. | $58.79 | 2025 | |
| Genmab U.S., INC. | $52.03 | 2025 | Tivdak |
| E.R. Squibb & Sons, L.L.C. | $50.82 | 2025 | Opdivo |
| Takeda Pharmaceuticals U.S.A., INC. | $49.85 | 2025 | Fruzaqla, Ninlaro |
| Pharmacosmos Therapeutics INC. | $39.66 | 2025 | Monoferric |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $38.54 | 2025 | Ojjaara |
| Bayer Healthcare Pharmaceuticals INC. | $38.29 | 2025 | |
| Pfizer INC. | $34.44 | 2025 | |
| Tactile Systems Technology INC | $28.32 | 2025 | Nimbl, Flexitouch Plus |
| Lilly USA, LLC | $28.12 | 2025 | Verzenio |
| Puma Biotechnology, INC. | $25.68 | 2025 | Nerlynx |
| Agios Pharmaceuticals, INC. | $24.11 | 2025 | Pyrukynd |
| Celgene Corporation | $23.40 | 2025 | Reblozyl |
| Genentech USA, INC. | $19.00 | 2025 | Polivy |
| Emd Serono, INC. | $18.89 | 2025 | |
| Servier Pharmaceuticals LLC | $18.75 | 2025 | |
| Tersera Therapeutics LLC | $16.52 | 2025 | Zoladex |
| Ani Pharmaceuticals, INC. | $16.11 | 2025 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minsung Jeong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.